NFSG
GTBP icon

Newbridge Financial Services Group’s GT Biopharma GTBP Stock Holding History

Newbridge Financial Services Group’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.84K Hold
150
– – ﹤0.01% 1081
2026
Q1 		$1.53K Hold
150
– – ﹤0.01% 1048
2025
Q4 		$2.94K Hold
150
– – ﹤0.01% 979
2025
Q3 		$2.2K Buy
150
+40
+36% +$1.49K ﹤0.01% 1125
2025
Q2 		$9.85K Buy
110
+40
+57% +$2.58K ﹤0.01% 892
2025
Q1 		$3.76K Hold
70
– – ﹤0.01% 835
2024
Q4 		$5.34K Buy
+70
New +$4.73K ﹤0.01% 851

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Newbridge Financial Services Group's GTBP Position: Q2 2026 in Review

Newbridge Financial Services Group held its GT Biopharma (GTBP) position steady in Q2 2026 at 150 shares worth $1.84K. The position accounts for ﹤0.01% of the portfolio, ranked #1081.

Newbridge Financial Services Group first reported a position in GTBP in Q4 2024 and has held it in 7 quarters since. The position peaked at $9.85K in Q2 2025. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Newbridge Financial Services Group held 150 shares of GT Biopharma worth $1.84K as of Q2 2026.
  • Newbridge Financial Services Group left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q2 2026, its #1081 holding.
  • Newbridge Financial Services Group first reported a position in GT Biopharma in Q4 2024 and has held it in 7 quarters since.
  • Newbridge Financial Services Group's GT Biopharma position peaked at $9.85K in Q2 2025.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Newbridge Financial Services Group's 13F filing for Q2 2026, filed 14 Aug 2026.